Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/1570159X13666150630173522 http://scihub22266oqcxt.onion/10.2174/1570159X13666150630173522 C4761633!4761633!26467411     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Neuropharmacol 2015 ; 13 (5): 616-35 Nephropedia Template TP {{tp|p=26467411|t=2015. Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics |pdf=|usr=}}{{26467411}} gab.com Text Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics JO: Curr Neuropharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26467411 #FOAvip Major depressive disorder (MDD) is associated with a significant burden and costs to the society. As remission of depressive symptoms is achieved in only one-third of the MDD patients after the first antidepressant trial, unsuccessful treatments contribute largely to the observed suffering and social costs of MDD. The present article provides a summary of the therapeutic strategies that have been tested for treatment-resistant depression (TRD). A computerized search on MedLine/PubMed database from 1975 to September 2014 was performed, using the keywords ?treatment-resistant depression?, ?major depressive disorder?, ?adjunctive?, ?refractory? and ?augmentation?. From the 581 articles retrieved, two authors selected 79 papers. A manual searching further considered relevant articles of the reference lists. The evidence found supports adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial. Also, in subjects resistant to two or more classes of antidepressants, some augmentation strategies and antidepressant combinations should be considered, although the overall response and remission rates are relatively low, except for fast acting glutamatergic modulators. The wide range of available treatments for TRD reflects the complexity of MDD, which does not underlie diverse key features of the disorder. Larger and well-designed studies applying dimensional approaches to measure efficacy and effectiveness are warranted. Twit Text FOAVip Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics ????Curr Neuropharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26467411 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26467411 #FOAvip English Wikipedia <ref>{{Cite pmid|26467411}}</ref> Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics #MMPMID26467411 de Sousa RT; Zanetti MV; Brunoni AR; Machado-Vieira R Curr Neuropharmacol 2015[Sep]; 13 (5): 616-35 PMID26467411show ga Major depressive disorder (MDD) is associated with a significant burden and costs to the society. As remission of depressive symptoms is achieved in only one-third of the MDD patients after the first antidepressant trial, unsuccessful treatments contribute largely to the observed suffering and social costs of MDD. The present article provides a summary of the therapeutic strategies that have been tested for treatment-resistant depression (TRD). A computerized search on MedLine/PubMed database from 1975 to September 2014 was performed, using the keywords ?treatment-resistant depression?, ?major depressive disorder?, ?adjunctive?, ?refractory? and ?augmentation?. From the 581 articles retrieved, two authors selected 79 papers. A manual searching further considered relevant articles of the reference lists. The evidence found supports adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial. Also, in subjects resistant to two or more classes of antidepressants, some augmentation strategies and antidepressant combinations should be considered, although the overall response and remission rates are relatively low, except for fast acting glutamatergic modulators. The wide range of available treatments for TRD reflects the complexity of MDD, which does not underlie diverse key features of the disorder. Larger and well-designed studies applying dimensional approaches to measure efficacy and effectiveness are warranted. äChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap f(epmc).pdf DeepDyve Pubget Overpricing